3-(2,5-dioxo-pyrrolidin-1-yl)propionaldehyde | 5615-85-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-(2,5-dioxo-pyrrolidin-1-yl)propionaldehyde
• 英文别名: N-(3-oxo-propyl)-succinimide；N-(3-Oxo-propyl)-succinimid；3-Succinimidopropionaldehyde；3-(2,5-dioxopyrrolidin-1-yl)propanal
• CAS: 5615-85-0
• 化学式: C₇H₉NO₃
• 分子量: 155.153
• InChiKey: CTVKWHKYDVIAGR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  54.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(2,5-dioxo-pyrrolidin-1-yl)propionaldehyde 在 sodium tetrahydroborate 、 sodium hydride 、 乙酰氯 作用下， 以 甲醇 为溶剂， 反应 34.5h， 生成 methyl 5-(2-methoxy-5-oxo-1-pyrrolidino)-2-pentenoate
  参考文献：
  名称：

  A practical preparation of the indolizidine nucleus: synthesis of (.+-.)-elaeokanine A

  摘要：

  Reduction of 3 followed by acid-catalyzed cyclization provides alpha,beta-unsaturated ester 5. As 3 can be prepared in two steps from succinimide, acrolein, and trimethyl phosphonoacetate, this is a practical method for the assembly of the indolizidine nucleus. The structure of 5 was secured by conversion to elaeokanine A, 7.

  DOI：

  10.1021/jo00003a064
• 作为产物：
  描述：

  N-(2-丙炔基)琥珀酰亚胺 在 ruthenium-based phosphine complex 水 作用下， 以 丙酮 为溶剂， 反应 72.0h， 生成 3-(2,5-dioxo-pyrrolidin-1-yl)propionaldehyde 、 1-(2-oxopropyl)pyrrolidine-2,5-dione
  参考文献：
  名称：

  自组装的双齿配体，用于Ru催化末端炔烃的抗Markovnikov水合反应。

  摘要：

  DOI：

  10.1002/anie.200503826

文献信息

• Polymeric prodrugs
  申请人：Complex Biosystems GmbH

  公开号：EP1579873A1

  公开（公告）日：2005-09-28

  A molecule is disclosed having the following structure: wherein T is D or A D being a residue of an amine containing biologically active molecule and A being a leaving group.

  揭示了具有以下结构的分子：其中T为D或AD，是含有生物活性分子的胺基残基，A为离去基团。
• An Approach toward Azacycles Using Photochemical and Radical Cyclizations of <i>N</i>-Alkenyl Substituted 5-Thioxopyrrolidin-2-ones
  作者：Albert Padwa、Martin N. Jacquez、Andreas Schmidt

  DOI：10.1021/jo035127w

  日期：2004.1.1

  thioxaphthalimido system containing an N-cycloalkenyl group in the side chain gave rise to products derived by γ-hydrogen abstraction from the n−π* triplet excited state. The photobehavior of the related N-3-alkenyl pyrrolidine-2,5-dithione system (62) was also studied and found to give products derived from both a 2 + 2 cycloaddition (63) and hydrogen atom transfer (64). Finally, the reaction of several N-alkenyl

  已经研究了一系列环状的N-烯基取代的硫代酰亚胺的光化学反应。辐照N -3-甲基丁-3-烯基-5-硫代-吡咯烷酮-2-酮（16）导致分子内[2 + 2]环加成，从而产生高应变的硫杂环丁烷17，并根据其结构确定了结构X射线分析。用四氟硼酸二甲基（甲硫基）s处理环加合物17，以良好的收率得到2,5,6,7-四氢吡咯嗪-3-酮（20）。用阮内镍进一步还原20得到5,5-二甲基六氢吡咯烷-1-酮（21）。该反应顺序证明了将2 + 2光加合物转化为吡咯烷核生物碱核心骨架的便利性。密切相关的N-丁烯基噻吩并吡咯烷酮一（22）的光化学反应以略有不同的方式进行，并以68％的收率生产了7-巯基甲基四氢吡咯烷酮3-一（24）。与上述结果相反，在侧链上含有N-环烯基的硫代邻苯二甲酰亚胺基体系的辐照产生了由γ-氢从n-π*三重态激发态提取的产物。相关的N -3-烯基吡咯烷-2,5-二硫酮体系的光行为（62）也被研究并发现得到衍生自2
• Protein-Proteophore complexes
  申请人：Complex Biosystems GmbH

  公开号：EP1525890A1

  公开（公告）日：2005-04-27

  The present invention relates to a protein encapsulated by an encapsulating organic compound (EOC) or proteophore wherein the protein and the encapsulating organic compound are present in 1:1 stoichiometry. In one embodiment of the present invention, the encapsulation is realized by an EOC protein inclusion compound EPIC according to the formula (I) in which the EMCs are connected to each other by one branching unit B under formation of a cavity which is vertically and horizontally open    and wherein the symbols have the following meanings: B:branching unit containing at least one branching center Bc and at least two branching functional groups Bfg connected to or capable of reacting with an encapsulating molecular chain EMC; EMC:encapsulating molecular chain; L:linker containing at least one functional group Lfg which is connected to the protein P or capable of connecting with functional groups present on the protein P under the formation of a chemical bond; 1:1, 2, 3, 4, 5, 6, 7, 8 or 9; P:pharmacologically active protein. In a further embodiment of the present invention, the encapsulation is realized by a macrocycle-protein inclusion compound MPIC according to the formula (IX) containing a protein P and a macrocyclic structure, and wherein the symbols have the meanings given above for formula (I). The EMCs can comprise substituents (capping groups), which can result in dendritic structures. The encapsulation assures a controlled release of a protein.

  本发明涉及由一个封装有机化合物（EOC）或蛋白质荷载体包裹的蛋白质，其中该蛋白质和封装有机化合物以1:1的化学计量比存在。在本发明的一个实施例中，封装是通过一个符合以下公式（I）的EOC蛋白质包含化合物EPIC实现的，其中EMCs通过一个分支单元B连接在一起，形成一个垂直和水平开放的空腔，符号的含义如下：B：包含至少一个分支中心Bc和至少两个连接到或能够与封装分子链EMC反应的分支功能基团Bfg的分支单元；EMC：封装分子链；L：包含至少一个与蛋白质P连接或能够在形成化学键时连接到蛋白质P上存在的功能基团Lfg的连接器；1:1、2、3、4、5、6、7、8或9；P：药理活性蛋白质。在本发明的另一个实施例中，封装是通过符合公式（IX）的大环-蛋白质包含化合物MPIC实现的，其中包含一个蛋白质P和一个大环结构，符号的含义如上所述。EMCs可以包括取代基（顶端基团），这可能导致树枝状结构。封装确保了蛋白质的受控释放。
• Process for Preparing Chiral Compounds
  申请人：Bauer David W.

  公开号：US20110118476A1

  公开（公告）日：2011-05-19

  The present invention is directed to a 2-deoxyribose-5-phosphate aldolase (DERA) chemoenzymatic process for making chiral compounds.

  本发明涉及一种2-脱氧核糖-5-磷酸醛缩酶（DERA）化学酶法制备手性化合物的方法。
• PRODRUG COMPRISING A DRUG LINKER CONJUGATE
  申请人：Cleemann Felix

  公开号：US20110053848A1

  公开（公告）日：2011-03-03

  The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein -D is an amine containing biologically active moiety; and -L is a non-biologically active linker moiety -L 1 represented by formula (I), wherein the dashed line indicates the attachment to the amine of the biologically active moiety and wherein R 1 , R 1a , R 2 , R 2a , R 3 , R 3a , X, X 1 , X 2 , X 3 have the meaning as indicated in the description and the claims and wherein L 1 is substituted with one to four groups L 2 -Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent; wherein L 2 is a single chemical bond or a spacer; and Z is a carrier group. The invention also relates to A-L, wherein A is a leaving group, pharmaceutical composition comprising said prodrugs and their use as medicaments.

  本发明涉及一种前药或其药学上可接受的盐，包括药物连接物D-L，其中-D是含有生物活性基团的胺基；而-L是非生物活性的连接基团-L1，由公式（I）表示，其中虚线表示连接到生物活性基团的胺基，其中R1、R1a、R2、R2a、R3、R3a、X、X1、X2、X3在说明书和权利要求中具有所示的含义，而L1用一到四个L2-Z基团取代并可选择进一步取代，前提是在公式（I）中标记为星号的氢未被取代；其中L2是单个化学键或间隔物；而Z是载体基团。本发明还涉及A-L，其中A是离去基团，以及包括所述前药的药物组合物及其作为药物的用途。